Management of Schizophrenia with Medical Disorders: Cardiovascular, Pulmonary, and Gastrointestinal

Psychiatric Clinics of North America

Volumn 32, Issue 4, 2009, Pages 759-773

  Short, Delmar D ^a,b   Hawley, Joanne M ^a,c   McCarthy, Maureen F ^a,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VIRGINIA TECH CARILION SCHOOL OF MEDICINE   (United States)

^c EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Anticholinergic; Atypical antipsychotic; QT prolongation

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; DROPERIDOL; DULOXETINE; ESCITALOPRAM; FLUVOXAMINE; HALOPERIDOL; KETOCONAZOLE; MESORIDAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PAROXETINE; PERPHENAZINE; PHENOTHIAZINE; PHENYTOIN; PIMOZIDE; PLACEBO; QUETIAPINE; QUINIDINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; UNINDEXED DRUG; ZIPRASIDONE;

ANTICHOLINERGIC SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG FATALITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; EMERGENCY TREATMENT; FECES IMPACTION; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HEART CONDUCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE EXTRASYSTOLE; HEPATITIS; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; LUNG DISEASE; LUNG EMBOLISM; MYOCARDITIS; ORTHOSTATIC HYPOTENSION; PERICARDIAL EFFUSION; PERICARDITIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QT PROLONGATION; QUALITY OF LIFE; RESPIRATION DEPRESSION; RESPIRATORY FAILURE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SLEEP APNEA SYNDROME; SYNCOPE; TACHYCARDIA; THORAX PAIN; TORSADE DES POINTES; URINE RETENTION; VEIN THROMBOSIS; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; EMERGENCY SERVICES, PSYCHIATRIC; GASTROINTESTINAL DISEASES; HUMANS; LUNG DISEASES; SCHIZOPHRENIA;

EID: 70649107854     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2009.09.005     Document Type: Review

References (48)

1. Newcomer J.W. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 68 Suppl 1 (2007) 20-27
2. Hennekens C.H., Hennekens A.R., Hollar D., et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 150 6 (2005) 1115-1121
3. Muir-Cochrane E. Medical co-morbidity risk factors and barriers to care for people with schizophrenia. J Psychiatr Ment Health Nurs 13 4 (2006) 447-452
4. Kane J.M., Leucht S., Carpenter D., et al. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary and summary. J Clin Psychiatry 64 Suppl 12 (2003) 5-19
5. Felker B., Yazel J.J., and Short D. Mortality and medical comorbidity among psychiatric patients: a review. Psychiatr Serv 47 12 (1996) 1356-1363
6. Sokal J., Messias E., Dickerson F.B., et al. Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. J Nerv Ment Dis 192 6 (2004) 421-427
7. Lambert T.J., Velakoulis D., and Pantelis C. Medical comorbidity and schizophrenia. Med J Aust 178 Suppl (2003) S67-S70
8. Mitchell A.J., and Malone D. Physical health and schizophrenia. Curr Opin Psychiatry 19 4 (2006) 432-437
9. Dickey B., Normand S.L., Weiss R.D., et al. Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv 53 7 (2002) 861-867
10. Compton M.T., Daumit G.L., and Druss B.G. Cigarette smoking and overweight/obesity among individuals with serious mental illnesses; a preventive perspective. Harv Rev Psychiatry 14 4 (2006) 212-222
11. Chou K.R., Chen R., Lee J.F., et al. The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. Int J Nurs Stud 41 3 (2004) 321-330
12. Osborn D.P., Levy G., Nazareth I., et al. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry 64 2 (2007) 242-249
13. Mortensen P.B. Neuroleptic medication and reduced risk of prostate cancer in schizophrenic patients. Acta Psychiatr Scand 85 5 (1992) 390-393
14. Carney C.P., Woolson R.F., Jones L., et al. Occurrence of cancer among people with mental health claims in an insured population. Psychosom Med 66 5 (2004) 735-743
15. Carney C.P., Jones L., and Woolson R.F. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. J Gen Intern Med 21 11 (2006) 1133-1137
16. Andreasen N.C., Kane J.M., Keith S., et al. Schizophrenia and other psychotic disorders. In: First M.B., and Ross R. (Eds). Diagnostic and Statistical Manual Text Revised tDSM-IV-TR (2000), American Psychiatric Association, Washington, DC 336
17. Preskorn S.H., and Irwin H.A. Toxicity of tricyclic antidepressants: kinetics, mechanism, intervention. J Clin Psychiatry 43 (1982) 151-156
18. Roose S.P., Glassman A.H., Giardina E.G.V., et al. Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry 44 (1987) 273-275
19. Pacher P., and Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?. Curr Pharm Des 10 20 (2004) 2463-2475
20. Koponen H., Alaräisänen A., Saari K., et al. Schizophrenia and sudden cardiac death: a review. Nord J Psychiatry 62 5 (2008) 342-345
21. Harrigan E.P., Miceli J.J., Anziano R., et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 24 1 (2004) 62-69
22. Ray W.A., Chung C.P., Murray K.T., et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360 3 (2009) 225-235
23. Daumit G., Goft D., Meyer J., et al. Antipsychotic effects on estimated 10 year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 105 1-3 (2008) 175-187
24. Gegenava M., and Kavtaradze G. Risk factors for coronary heart disease in patients with schizophrenia. Georgian Med News 134 (2006) 55-58
25. Glassman A.H. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry 66 Suppl 6 (2005) 5-10
26. Vieweg W.V. New generation antipsychotic drugs in QTc interval prolongation. Prim Care Companion J Clin Psychiatry 5 5 (2003) 205-215
27. Ames D., Camm J., Cook P., et al. Minimizing the risk associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety and Schizophrenia Group. Encephale 28 6 pt 1 (2002) 552-562
28. Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs 17 6 (2003) 423-430
29. Czekalla J., Beasley Jr. C.M., Dellva M.A., et al. Analysis of the QTc interval during the olanzapine treatment of patients with schizophrenia in related psychosis. J Clin Psychiatry 62 3 (2001) 191-198
30. Czekalla J., Kollack-Walker S., and Beasley Jr. C.M. Cardiac safety perimeters of olanzapine: comparison with other atypical and typical antipsychotics. J Clin Psychiatry 62 Suppl 2 (2001) 35-40
31. Wilton L.D., Heeley E.L., Pickering R.M., et al. Comparative study of the mortality rates in cardiac dysrythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol 15 2 (2001) 120-126
32. Lawrence K.R., and Nasraway S.A. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy 17 3 (1997) 531-537
33. Riker R.R., Fraser G.L., and Cos P.M. Continuous infusion of haloperidol controls agitation in critically ill patients. Crit Care Med 22 3 (1994) 433-440
34. Ravin D.S., and Levenson J.W. Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother 31 7-8 (1997) 867-870
35. Borison R.L., Arvanitis L.A., and Miller B.G. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 16 2 (1996) 158-169
36. Garver D.L. Review of quetiapine side effects. J Clin Psychiatry 61 Suppl 8 (2000) 31-33 [discussion: 34-5]
37. Lehman AF, Leiberman JA, Dixon LB, et al. Practice Guidelines for the Treatment of Patients with Schizophrenia. In: Quick CM, Adams DC, Bowden CL, et al, editors. APA Practice Guidelines for the treatment of psychiatric disorders. 2nd edition. p. 616.
38. Lehman AF, Leiberman JA, Dixon LB, et al. Practice Guidelines for the Treatment of Patients with Schizophrenia. In: Quick CM, Adams DC, Bowden CL, editors. APA Practice Guidelines for the treatment of psychiatric disorders. 2nd edition. p. 592.
39. Chengappa K.N., Pollock B.G., Parepally H., et al. Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. J Clin Psychopharmacol 20 3 (2002) 311-316
40. Dumortier G., Cabaret W., Stamatiadis L., et al. Hepatic tolerance of atypical antipsychotic drugs. Encephale 28 6 Pt 1 (2002) 542-551
41. Ozcanli T., Erdogan A., Ozdemir S., et al. Severe liver enzyme elevations after three years of olanzapine treatment: A case report and review of olanzapine associated hepatotoxicity. Prog Neuropsychopharmacol Biol Psychiatry 30 6 (30, 2006) 1163-1166 Epub 2006 Apr 24
42. Wyszynski A.A. The patient with hepatic disease alcohol dependence and altered mental status. In: Wyszynski A.A., and Wyszynski B. (Eds). Manual of psychiatric care for the medically ill (2005), American Psychiatric Publishing, Inc, Washington, DC 40-46
43. Siris S.G., and Rifkin A. The problem of psychopharmacotherapy in the medically Ill. Psychiatr Clin North Am 4 2 (1981) 379-390
44. Jabeen S., Polli S.I., and Gerber D.R. Acute respiratory failure with a single dose of quetiapine fumarate. Ann Pharmacother 40 3 (2006) 559-562
45. Cohn M.A., Morris D.D., and Juan D. Effects of estazolam and flurazepam on cardiopulmonary function in patients with chronic obstructive pulmonary disease. Drug Saf 7 (1992) 152-158
46. Rund D.A., Ewing J.D., Mitzel K., et al. The use of intramuscular benzodiazepines and antipsychotic agents in the treatment of acute agitation or violence in the emergency department. J Emerg Med 31 3 (2006) 317-324
47. Devane C.L. Drug interactions. In: Stein D., Lerer B., and Sthl S. (Eds). Evidence based psychopharmacology (2005), Cambridge Univeristy Press, New York 320-337
48. Boyer E.W., and Shannon M. The serotonin syndrome. N Engl J Med 352 (2005) 1112-1120